Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Deoxycytidine. Found 31 abstracts

no pagination
Shaikh T, Wang LS, Egleston B, Burki M, Hoffman JP, Cohen SJ, Meyer JE. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol. 2018 Jan;41(1):59-64.   PMCID: PMC4769977
Ursu O, Gosline SJ, Beeharry N, Fink L, Bhattacharjee V, Huang SC, Zhou Y, Yen T, Fraenkel E. Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens. PLoS One. 2017 Oct;12(10):e0185650.   PMCID: PMC5638242
Li D, Moughan J, Crane C, Hoffman JP, Regine WF, Abrams RA, Safran H, Liu C, Chang P, Freedman GM, Winter KA, Guha C, Abbruzzese JL. RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704. Int J Radiat Oncol Biol Phys. 2016 Mar;94(3):554-60.   PMCID: PMC4876948
Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, Shepherd FA, Chen AC, Shen Y, Nathan FE, Harbison CT, Antonia S. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Sep;34(25):2969-79.   PMCID: PMC5569693
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract I. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug;121(15):2586-93.
Rixe O, Puzanov I, LoRusso PM, Cohen RB, Morris JC, Olowokure OO, Yin JY, Doroumian S, Shen L, Olszanski AJ. Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies. Anti-Cancer Drugs. 2015 Aug;26(7):785-92.   PMCID: 4484664
Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, Wapnir IL, Carlson RW, Chang PJ, Sparano JA, Head B, Goldstein LJ, Haley B, Dakhil SR, Reid JE, Hartman AR, Manola J, Ford JM. Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. J Clin Oncol. 2015 Apr 06;33(17):1895-901.   PMCID: 4451172
Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG. Efficacy Endpoints of Radiation Therapy Group Protocol 0247: A Randomized, Phase 2 Study of Neoadjuvant Radiation Therapy Plus Concurrent Capecitabine and Irinotecan or Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics. 2015 Jan;91(1):116-23.   PMCID: 4385459
Dotan E, Meropol NJ, Burtness B, Denlinger CS, Lee J, Mintzer D, Zhu F, Ruth K, Tuttle H, Sylvester J, Cohen SJ. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. J Gastrointest Cancer. 2012 Dec;43(4):562-9.   PMCID: 3400721
Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009 Mar 20;27(9):1419-25.   PMCID: PMC 2668552
Konski A, Li T, Sigurdson E, Cohen SJ, Small W, Spies S, Yu JQ, Wahl A, Stryker S, Meropol NJ. Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys. 2009 May;74(1):55-9.   PMCID: PMC2933375
Huang CH, Millenson MM, Sherman EJ, Borghaei H, Mintzer DM, Cohen RB, Staddon AP, Seldomridge J, Treat OJ, Tuttle H, Ruth KJ, Langer CJ. Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy. J Thorac Oncol. 2008 Sep;3(9):1032-8.
Small W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, McGinn CJ. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008 Feb 20;26(6):942-7.
Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.[see comment]. Journal of Clinical Oncology. 2006 Sep;24(25):4069-77.
Talamonti MS, Small W, Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, Zalupski MM, Hoffman JP, Freedman GM, Kinsella TJ, Philip PA, McGinn CJ. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Annals of Surgical Oncology 13 (2): 150-158 Feb 2006. 2006 Feb;13(2):150-8.
Bookman MA. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. International Journal of Gynecological Cancer. 2005 May;15 Suppl 1:12-7.
Ozols RF. Gemcitabine and carboplatin in second-line ovarian cancer. Semin Oncol. 2005 Aug;32(4 Suppl 6):S4-8.
Langer CJ. Irinotecan in advanced lung cancer: focus on North American trials. Oncology (Huntington). 2004 Jun;18(7 Suppl 4):17-28.
Langer CJ. The global role of irinotecan in the treatment of lung cancer: 2003 update. Oncology (Huntingt). 2003 Jul;17(7 Suppl 7):30-40.
Sasson AR, Wetherington RW, Hoffman JP, Ross EA, Cooper H, Meropol NJ, Freedman G, Pingpank JF, Eisenberg BL. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. International Journal of Gastrointestinal Cancer. 2003 Jan;34(2-3):121-8.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Deoxycytidine

Deoxycytidine Female Antineoplastic Combined Chemotherapy Protocols Middle Aged Aged therapeutic use Male analogs & derivatives administration & dosage drug therapy Adult pathology Neoplasm Staging mortality 80 and over Aged Survival Analysis Fluorouracil Pancreatic Neoplasms Treatment Outcome Disease-Free Survival Neoadjuvant Therapy Survival Rate therapy methods adverse effects Carboplatin Cisplatin derivatives Drug Administration Schedule 951-77-9 (Deoxycytidine) Camptothecin aa [Analogs & Derivatives] Antineoplastic Antimetabolites dt [Drug Therapy] Lung Neoplasms Adenocarcinoma Chemoradiotherapy metabolism pharmacokinetics Non-Small-Cell Lung Carcinoma adverse Cohort Studies Taxoids Drug Dose-Response Relationship 103882-84-4 (gemcitabine) Ovarian Neoplasms Local Neoplasm Recurrence surgery Adjuvant Radiotherapy Retrospective Studies effects genetics ad [Administration & Dosage] radiotherapy Antineoplastic) 0 (Antimetabolites Etoposide Neoplasm Invasiveness Maximum Tolerated Dose tu [Therapeutic Use] Organoplatinum Compounds Radiotherapy Dosage Rectal Neoplasms Doxorubicin analogs & me [Metabolism] Human Prognosis Predictive Value of Tests 7689-03-4 (Camptothecin) Non-US Gov't Research Support Colorectal Neoplasms Antineoplastic Agents Kaplan-Meier Estimate tu [Therapeutic Use] administration & 0 (Antineoplastic Combined Chemotherapy Protocols) analogs & Adjuvant Chemotherapy Salvage Therapy Vindesine 100286-90-6 (irinotecan) 51-21-8 (Fluorouracil) Mitomycin dosage Biological Tumor Markers pa [Pathology] Muscle Neoplasms Fibrosis et [Etiology] Paclitaxel gemcitabine plus cisplatin Intensity-Modulated Radiotherapy Reverse Transcriptase Polymerase Chain Reaction etiology biosynthesis drug effects Benzamides Analysis of Variance Feasibility Studies doxorubicin Phosphorylation EC 1-3-1-2 (Dihydrouracil Dehydrogenase (NADP)) Epidermal Growth Factor Receptor Algorithms physiopathology Neoplastic Gene Expression Regulation Randomized Controlled Trials Japan Triple Negative Breast Neoplasms Genetic Polymorphism ge [Genetics] Urinary Bladder Neoplasms statistics & numerical data Thymidine Phosphorylase Methotrexate Phytogenic Antineoplastic Agents neoadjuvant North America Ribonucleotide Reductases United States 154361-50-9 (capecitabine) Pemetrexed Neoplasm DNA Neutropenia Protein Kinase Inhibitors ch [Chemistry] Fluorodeoxyglucose F18 immunology Genomic Instability Effects] Non-US Gov't Support Vinblastine chemically induced Hematologic Diseases BRCA2 Protein Genetic Transcription Multiple Drug Resistance Phase III Clinical Trials ae [Adverse vinblastine Monoclonal Antibodies-Humanized pharmacology RecQ Helicases Conformal Radiotherapy methotrexate secondary radionuclide imaging Peritoneal Neoplasms Genetic Epigenesis
Last updated on Friday, January 03, 2020